By Fineline Cube Novartis AG (NYSE: NVS) announced that the biomarker cohort of the FORTITUDE Phase I/II clinical study of del-brax (delpacibart braxlosiran) met its primary and key secondary endpoints. Reductions in the levels of the biomarkers KHDC1L (cDUX) and creatine kinase in patients indicate potent target engagement and a reduction in muscle damage in individuals with facioscapulohumeral muscular dystrophy (FSHD).
Clinical Development Status
| Item | Detail |
|---|---|
| Study | FORTITUDE Phase I/II |
| Cohort | Biomarker cohort |
| Endpoints Met | Primary and key secondary endpoints |
| Biomarkers Reduced | KHDC1L (cDUX) and creatine kinase |
| Indication | Facioscapulohumeral muscular dystrophy (FSHD) |
| Therapy Class | Antibody-oligonucleotide conjugate (AOC) |
| Development Stage | Late-stage clinical development |
Drug Profile & Mechanism of Action
- Molecule: Del-brax (delpacibart braxlosiran) – investigational therapy
- Platform: Antibody-oligonucleotide conjugate (AOC), a novel class of RNA therapy
- Innovation: Potential to become the first disease-modifying therapy for FSHD, a rare, irreversible neuromuscular disease characterized by progressive loss of muscle function and increasing disability
- Acquisition Path: Added to Novartis’ neuroscience pipeline through the acquisition of Avidity Biosciences, completed in February 2026
- Pipeline Position: One of three late-stage, first-in-class potential disease-modifying AOC therapies from the Avidity acquisition
Clinical Evidence – Biomarker Results
| Endpoint | Result (Del-brax) | Significance |
|---|---|---|
| KHDC1L (cDUX) Reduction | Statistically significant decrease | Indicates potent target engagement |
| Creatine Kinase Reduction | Statistically significant decrease | Demonstrates reduction in muscle damage |
| Safety Profile | Not disclosed in current announcement | To be detailed in future communications |
| Patient Population | Individuals with FSHD | Rare disease affecting approximately 1 in 20,000 people globally |
The biomarker data provides strong evidence of biological activity and supports advancing del-brax into later-stage clinical development as a potential disease-modifying treatment for FSHD.
Market Impact & Strategic Outlook
- Rare Disease Landscape: FSHD currently has no approved disease-modifying therapies, creating significant unmet medical need
- Commercial Potential: As a first-in-class therapy for a rare neuromuscular condition, del-brax could command premium pricing and extended market exclusivity
- Pipeline Enhancement: The Avidity acquisition strengthens Novartis’ position in innovative RNA therapeutics and rare neurological disorders
- Competitive Advantage: The AOC platform enables targeted delivery of oligonucleotides to specific tissues, potentially improving efficacy while reducing off-target effects compared to conventional approaches
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for del-brax. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech